文献速递临床微生物质量管理与危急值

抗菌药物敏感性试验设备在CLSI、EUCAST、ISO、FDA和EMA框架下的性能评估:对折点应用的影响

Performance evaluation of antimicrobial susceptibility testing devices across CLSI, EUCAST, ISO, FDA, and EMA frameworks: implications for breakpoint application.
PubMed 文献 · J Clin Microbiol · 2026-10-13

该综述比较了CLSI、EUCAST、ISO等标准制定机构和FDA、IVDR等监管框架对肉汤微量稀释替代方法(纸片扩散法和商业MIC系统)的性能评估要求。各框架在必要一致性、分类一致性、错误率等指标上存在显著异质性,CLSI和FDA侧重折点依赖的分类一致性和错误率,ISO侧重分析性指标,EUCAST分析上对齐ISO但独立设定折点。这些差异可导致设备评估结果不一致,尤其在中低收入国家影响耐药监测和抗菌药物管理。

要点

  • CLSI和FDA强调折点依赖的分类一致性和错误率,ISO强调必要一致性和偏倚等分析指标。
  • EUCAST在分析性能上与ISO一致,但独立负责折点设定。
  • 替代MIC方法在折点附近与BMD相关,但跨MIC范围可能出现系统偏倚。

核心结论

  • 不同标准制定组织和监管框架对AST设备评估存在显著异质性,可导致不一致的设备评估和药敏解释。
  • 需要加强协调并认识方法学局限性,以确保可靠的AST报告并支持全球抗菌药物耐药努力。

研究设计与样本

  • 小型综述,比较CLSI、EUCAST、ISO等标准制定组织和FDA、IVDR等监管框架的评估框架。
  • 分析必要一致性、分类一致性、错误率、重现性和偏倚等关键性能指标,以及折点设定和设备审批路径差异。

主要发现

  • CLSI和FDA强调折点依赖的分类一致性和错误率,ISO优先分析性指标如必要一致性和偏倚而不含分类错误。
  • EUCAST分析上与ISO broadly一致,但独立维护折点设定责任。
  • 替代MIC方法在折点附近常与BMD相关,但跨MIC范围可显示系统偏倚,必要一致性 alone 不能完全捕捉。

关键数值与推荐

  • CLSI和FDA框架侧重分类一致性和错误率,且依赖折点。
  • ISO框架优先必要一致性和偏倚等分析指标,不包含分类错误。
  • EUCAST分析上 broadly 与ISO一致,但单独负责折点设定。

临床怎么用

  • 实验室应了解所用评估框架与本地折点系统的匹配性,尤其在折点修订后。
  • 中低收入国家实验室需注意替代MIC方法的系统偏倚,结合必要一致性和分类一致性综合评估设备。

局限性

  • 为小型综述,未报告系统检索策略或纳入研究数量。
  • 未提供具体性能数值或Meta分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Broth microdilution (BMD) remains the reference standard for determining minimum inhibitory concentrations (MICs) in antimicrobial susceptibility testing (AST). However, most routine laboratories rely on surrogate methods, including disk diffusion and commercial MIC-generating systems, whose results must correlate with those of reference BMD prior to clinical use. Evaluation criteria differ across standards development organizations (SDOs) and regulatory authorities, potentially affecting clinical interpretation, particularly in low- and middle-income countries (LMICs). This mini-review compares evaluation frameworks from major SDOs-the Clinical and Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial Susceptibility Testing (EUCAST), and the International Organization for Standardization (ISO)-and regulatory frameworks, including the U.S. Food and Drug Administration (FDA) and the European In Vitro Diagnostic Regulation (IVDR). Key performance metrics, including essential agreement, categorical agreement, error rates, reproducibility, and bias, were analyzed, alongside differences in breakpoint setting and device approval pathways. Implications for clinical microbiology and antimicrobial stewardship were considered, with explicit emphasis on challenges faced in LMIC settings. Substantial heterogeneity exists across frameworks. CLSI and FDA emphasize breakpoint-dependent categorical agreement and error rates, whereas ISO prioritizes analytical measures such as essential agreement and bias without categorical errors. EUCAST broadly aligns with ISO analytically while separately maintaining responsibility for breakpoint setting. These differences can yield discordant device assessments, especially after breakpoint revisions. Surrogate MICs often correlate with BMD near breakpoints but may show systematic bias across MIC ranges, not fully captured by essential agreement alone, with important implications for LMIC laboratories. Divergent frameworks influence susceptibility interpretation, resistance surveillance, and antimicrobial stewardship, particularly in LMICs. Greater harmonization and awareness of methodological limitations are essential to ensure reliable AST reporting and support global antimicrobial resistance efforts across LMIC healthcare systems.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Shindikar A, Mahesh R, Periasamy H, et al. Performance evaluation of antimicrobial susceptibility testing devices across CLSI, EUCAST, ISO, FDA, and EMA frameworks: implications for breakpoint application. J Clin Microbiol. 2026. PMID: 42867468. doi:10.1128/jcm.00643-26

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。